Stock Analysis of Otonomy Inc (OTIC) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code OTIC
Close 0.0085
Change -0.107 / 92.64 %
Volume 1943.47 K
Vol Change 1653.48 K / 570.20 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bearish
Growth Index Very Low Growth Stock
Value Index No Significant Value
Profitability Index Poor Profitability Stock
Stability Index Very Low Stability Stock


Fundamental View of Otonomy Inc
PE (TTM)

-0.0111

Very Poor
Price / Book

0.0132

Excellent
Price / Sales

4443393

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

582482

Enterprise Value

-57377.52 K

ROA (TTM)

-63.73

Very Poor
ROE (TTM)

-119.77

Very Poor
Net Margin (TTM)

-40200000000.00

Very Poor
Revenue

54.21 %

125000
Net Profit

14.42 %

-51181.00 K
Debt to Equity

0.354

Very Good
Altman Z Score

-8.98

Very Poor
Quick Ratio

0

Poor
Cash Ratio

6.28

Excellent


Highs/Lows of Otonomy Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.115 92.61 % 1.54 % 0.11650.007510-Apr-2311-Apr-23
Two Week0.114 92.54 % 3.42 % 0.1170.007531-Mar-2311-Apr-23
One Month0.109 92.20 % 5.60 % 0.1170.007531-Mar-2311-Apr-23
Three Month0.097 91.24 % 5.95 % 0.1250.007524-Jan-2311-Apr-23
Six Months0.259 96.72 % 17.48 % 0.3320.007530-Nov-2211-Apr-23
One year2.18 99.61 % 27.52 % 2.540.007520-Apr-2211-Apr-23
Two year2.23 99.62 % 29.70 % 2.590.007522-Mar-2211-Apr-23
Five year4.125 99.79 % 85.46 % 2.540.007520-Apr-2211-Apr-23


Technical View of Otonomy Inc
RSI

8.55

Mild Bullish
MACD

-0.0064

Strong Bearish
ADX

33.47

Bearish
Super Trend

0.054

Mild Bearish
Williams %R

-99.09

Mild Bearish
CCI

-661.56

Mild Bullish


EMA 5

0.079

Strong Bearish
EMA 15

0.100

Strong Bearish
EMA 50

0.109

Bearish
EMA 100

0.177

Strong Bearish
SMA 100

0.109

Neutral
SMA 200

0.410

Strong Bearish
SMA 5 / 20

0.094 / 0.106

Strong Bearish
SMA 15 / 50

0.106 / 0.107

Strong Bearish
SMA 50 / 200

0.107 / 0.410

Mild Bearish




Charts of Otonomy Inc


Returns of Otonomy Inc with Peers
Period / StockOTICCANOBTTXONCS
1 Week-92.61%-90.00%2.75%-65.73%
1 Mth-92.20%-92.83%24.44%-78.07%
3 Mth-91.24%-97.14%-94.87%-91.95%
6mth-96.72%-99.49%-94.67%-95.15%
1 Year-99.61%-99.87%-98.58%-99.40%
2 Year-99.62%-99.97%-99.30%-99.85%
5 Years-99.79%---99.97%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Otonomy Inc with Peers
Ratio / StockOTICCANOBTTXONCS
PE-0.0111-0.707-3.82-0.0023
P/B0.01320.864-40.350.0101
ROA-63.73-23.89-296.43-135.70
ROE-119.77-222.100-440.55
Debt To Equity0.354000.335
Revenue125000
54.21 % 		3102.10 M
13.26 % 		0
% 		0
%
Net Income-51181.00 K
14.42 % 		-577761.00 K
178.75 % 		-31573.00 K
20.59 % 		-34179.63 K
24.33 %


Technicals of Otonomy Inc with Peers
Technical / StockOTICCANOBTTXONCS-
ADX33.4728.6616.9716.48
CMF-0.260-0.0371-0.525-0.508
MFI57.4461.9729.1893.35
RSI8.5518.2440.7522.70
MACD Abv SignalFalseFalseTrueFalse
Price Above 50 MAFalseFalseFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : Otonomy Inc

Address : 4796 Executive Drive, San Diego, CA, United States, 92121
Tel : 619 323 2200
URL : https://www.otonomy.com
Code : OTIC, ISIN : US68906L1052, Exchange : PINK, Country : USA
Fiscal Year End : December
IPO date : 13_Aug_2014
Employee Count : 51

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.


Note : All Data Generated at the End of Trading Hours (EOD Data)